Related Experiment Video
Updated: Mar 31, 2026
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
948
S100A16 is a Prognostic Marker for Lung Adenocarcinomas
Keita Saito1, Makoto Kobayashi, Ryo Nagashio
1Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Kanagawa, Japan
Asian Pacific Journal of Cancer Prevention : APJCP
|October 31, 2015
Summary
S100A16 protein is overexpressed in lung adenocarcinoma and its membranous expression indicates a poor prognosis. This finding identifies S100A16 as a novel prognostic marker for lung adenocarcinoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Proteomics
Background:
- Low-molecular weight proteins and peptides are crucial for cellular functions.
- Identifying novel biomarkers is essential for early cancer detection and treatment.
Purpose of the Study:
- To identify proteins that regulate lung adenocarcinoma (AC) function.
- To evaluate the potential of these proteins as novel tumor markers for AC.
Main Methods:
- Utilized tricine-SDS polyacrylamide gel electrophoresis (tricine 2-DE) to detect proteins under 1 kDa.
- Performed immunohistochemical analysis on 170 lung AC tissues to validate protein expression and localization.
Main Results:
- Tricine 2-DE identified five overexpressed proteins in lung AC cells, including S100A16.
- Membranous S100A16 staining correlated significantly with advanced pathological stage, invasiveness, and poorer overall survival in lung AC patients.
- Multivariate analysis confirmed S100A16 as an independent adverse prognostic indicator.
Conclusions:
- S100A16 protein is overexpressed in lung adenocarcinoma.
- Membranous expression of S100A16 serves as a novel and independent prognostic marker for lung AC.
